Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. (Nasdaq: ARDX) is a biopharmaceutical company focused on first-in-class medicines based on inhibition of the sodium/hydrogen exchanger 3 (NHE3). Its news flow centers on the commercial performance and clinical profile of its tenapanor-based products, IBSRELA and XPHOZAH, as well as progress in its pipeline and corporate developments.
News releases from Ardelyx frequently cover product revenue trends for IBSRELA, indicated for irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH, indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy when phosphate binders are inadequate or not tolerated. The company provides updates on quarterly and annual product revenue, preliminary financial results and strategic outlooks for future years.
Investors and observers can also expect coverage of clinical and real-world evidence presented at major medical meetings. Ardelyx has reported data on IBSRELA at the American College of Gastroenterology’s Annual Scientific Meeting, including patient treatment satisfaction, reductions in abdominal bloating and analyses suggesting potential reductions in healthcare resource utilization. For XPHOZAH, the company has highlighted real-world effectiveness and patient satisfaction data presented at the American Society of Nephrology’s Kidney Week, focusing on serum phosphate reduction in dialysis patients with hyperphosphatemia.
Additional Ardelyx news items include participation in healthcare and investor conferences, executive leadership changes, financing and loan amendments, and updates on the development of RDX10531, a next-generation NHE3 inhibitor. The ARDX news page on Stock Titan aggregates these announcements, allowing readers to follow product performance, clinical data disclosures and key corporate events over time.
Ardelyx (Nasdaq: ARDX) announced publication of a peer‑reviewed post‑hoc analysis titled “Tenapanor is associated with earlier and sustained symptom relief in IBS‑C” in Therapeutic Advances in Gastroenterology.
Pooled data from one Phase 2b and two Phase 3 trials showed increased bowel movement frequency by 2 weeks, meaningful abdominal symptom relief by 4–5 weeks, and greater likelihood of sustained benefit through 12 weeks. No new safety signals were reported; transient mild‑to‑moderate diarrhea was most common.
Ardelyx (Nasdaq: ARDX) announced participation in two investor events in Miami the week of March 10, 2026: the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit.
The company will present at Leerink on March 10 at 4:20 p.m. ET with 1x1 meetings on March 10 and 11. A live webcast will be available on the Events and Presentations page at ir.ardelyx.com; a replay will be hosted for 30 days after the Leerink presentation.
Ardelyx (Nasdaq: ARDX) announced a multi-year partnership with the LPGA to raise awareness and reduce stigma around digestive health, specifically irritable bowel syndrome with constipation (IBS-C).
The collaboration will use LPGA platforms, digital content, player ambassadors and onsite activations throughout the 2026 season to educate and connect patients.
Ardelyx (Nasdaq: ARDX) reported full-year 2025 results with total revenue of $407.3 million and IBSRELA revenue of $274.2 million (73% YoY). XPHOZAH generated $103.6 million. Cash and short-term investments were $264.7 million as of December 31, 2025. The company launched a Phase 3 CIC trial (ACCEL) and expects FDA submission timing contingent on results.
Management guided 2026 IBSRELA revenue to $410–$430 million and XPHOZAH to $110–$120 million; net loss was $61.6 million for 2025.
Ardelyx (Nasdaq: ARDX) will report full year and fourth quarter 2025 results and host a conference call on Thursday, February 19, 2026 at 4:30 p.m. Eastern Time. The call will feature the executive leadership team and include a business update.
Live audio will be webcast via the Investors section at the company's website and archived for replay for 30 days.
Ardelyx (Nasdaq: ARDX) announced that the USPTO issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor”, covering the commercial formulations of IBSRELA and XPHOZAH, with an expiration date of November 26, 2042.
The company said it will submit the patent for listing in the FDA Orange Book. The November 26, 2042 expiry reflects a Patent Term Adjustment due to USPTO delays and updates prior communications.
Ardelyx (Nasdaq: ARDX) announced the first patient has been dosed in ACCEL, a Phase 3 trial evaluating IBSRELA (tenapanor) for chronic idiopathic constipation (CIC).
ACCEL is randomized, double-blind, placebo-controlled, plans ~700 patients, twice-daily dosing for 26 weeks, enrollment through 2026 and topline data expected in H2 2027. Safety notes include diarrhea rates and a pediatric dehydration boxed warning.
Ardelyx (Nasdaq: ARDX) reported preliminary, unaudited 2025 product revenue of approximately $378 million with IBSRELA generating about $274 million$104 million for 2025 with ~$28 million in Q4. The company ended 2025 with $265 million in cash, cash equivalents and investments. Guidance: 2026 IBSRELA revenue is expected at $410–430 million (≥50% growth vs. 2025) and XPHOZAH at $110–120 million. Long-term outlook projects IBSRELA reaching $1 billion revenue by 2029. Corporate updates include a Phase 3 CIC trial commencing and a Notice of Allowance for a patent expiring December 6, 2041.
Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of XPHOZAH (tenapanor) at ASN Kidney Week on November 7, 2025. Key findings: real-world initiators experienced an average serum phosphate reduction of ~1.0 mg/dL, with 45.3% of patients reducing ≥1 mg/dL and 25.1% reducing ≥2 mg/dL over a 120-day follow-up. A patient survey reported 63% felt phosphate levels were better and 69% reported improved outlook on control. Additional posters showed improved bowel movements in ESKD patients and a Japan cost-effectiveness analysis meeting a 5 million JPY willingness-to-pay threshold.
Ardelyx (Nasdaq: ARDX) management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT / 11:30 am ET. Investors can watch a live webcast via the Events and Presentations page on the Ardelyx website. A replay will be available on the Ardelyx website for 30 days after the event.
The presentation offers a chance to hear management commentary and corporate updates directly; access is through the company website's investor events page.